Form 4: Health Catalyst Director Sells 4,500 Shares Under 10b5-1 Trading Plan

Health Catalyst director Duncan Gallagher sold 4,500 shares of common stock at $6.9812 per share on December 23, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Director Duncan Gallagher of Health Catalyst, Inc. sold 4,500 shares of common stock.
• The sale occurred on December 23, 2024.
• The price per share was $6.9812.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 26, 2024.
• Following the transaction, Gallagher directly owns 74,438 shares of Health Catalyst stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider sale under a pre-arranged plan, which is neither positive nor negative. It's a neutral event.

Risks

• Sales by insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

This is a routine disclosure of an insider stock sale, which is common in publicly traded companies. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any recent non-public information.

Comparison to Industry Standards

• Insider sales are a common occurrence in publicly traded companies, and the use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.
• Comparable companies also have similar filings when directors or officers sell shares.

Stakeholder Impact

• The sale may have a minor impact on shareholder sentiment, but it is unlikely to be significant given the pre-planned nature of the transaction.

Key Dates

Keywords

Health Catalyst, insider trading, stock sale, Form 4, Duncan Gallagher, 10b5-1 plan, director